Drug Profile

Morphine-6-glucuronide - PAION

Alternative Names: CEE 04410; M6G

Latest Information Update: 25 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CeNeS Pharmaceuticals
Developer PAION; Yichang Humanwell Pharmaceutical
Class Morphine derivatives; Opioid analgesics
Mechanism of Action Opioid mu receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase Unknown Postoperative pain

Most Recent Events

05 Nov 2014 Morphine-6-glucuronide licensed to Yichang Humanwell Pharmaceutical in China
03 Nov 2008 Adverse events data from a Meta-analysis of Phase-II and Phase-III trials in Postoperative pain released by PAION
24 Jun 2008 CeNeS has been acquired by PAION

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com